We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Biotech Acquisition Designed to Accelerate the Development and Marketing of Immunosequencing Applications

By LabMedica International staff writers
Posted on 19 Jan 2015
Print article
Adaptive Biotechnologies Corp. (Seattle, WA, USA), a developer of next-generation sequencing (NGS) to profile T-cell and B-cell receptors, has acquired of Sequenta, Inc. (South San Francisco, CA, USA), which is expected to expedite and expand the use of innovative immunosequencing technology for researchers and clinicians to diagnose, treat, and monitor patients with cancer, autoimmune disorders, and infectious diseases.

Immunosequencing, which uses NGS to quantitatively characterize the adaptive immune system, represents a multi-billion dollar opportunity given the role the immune system plays in nearly all areas of healthcare. Up to now, Adaptive has mostly focused on developing strategies and services for researchers, and Sequenta has focused on developing similar technology for use in monitoring of minimal residual disease (MRD) for patients with blood cancers. Adaptive and its collaborators also have released exciting research on the use of immunosequencing to measure the immune response to solid tumors and to immunotherapeutic drugs designed to enhance the response to cancer, which is the fastest growing class of new drugs for cancer patients.

“Our mission is to change the course of medicine through sequencing a patient's adaptive immune system. Over the past few months it has become increasingly clear that joining forces with Sequenta would accelerate our ability to make the promise of immunosequencing a reality for physicians and patients,” said Chad Robins, CEO of Adaptive. “By combining our resources, we can increase the number of clinical trials we are able to run to validate clinical applications of immunosequencing, and explore new and innovative research and development initiatives that neither of us would have been able to do alone.”

The companies anticipate a complementary integration of talent across senior management, R&D, bioinformatics, and sales. Sequenta founders Tom Willis and Malek Faham will join Adaptive’s senior leadership team reporting to Chad Robins, who will remain CEO of the combined company. Dr. Willis and Dr. John Stuelpnagel, Sequenta’s chairman, Illumina co-founder, and chairman of Ariosa Diagnostics, also will join Adaptive’s board of directors.

In addition to expanding the use of its research platform for academic and pharmaceutical researchers, the combined company will focus comprehensively on marketing the technology for measuring MRD in blood cancers. “We believe immunosequencing represents a more sensitive and accurate alternative to the current standard of care used to detect MRD in patients with blood cancers, including flow cytometry. Together, we can accelerate the adoption of this technology in clinical practice and in clinical trials for revolutionary new therapies that use MRD to determine patient specific care paradigms,” said Dr. Willis.

Chad Robins presented on behalf of the new combined company at the J.P. Morgan 33rd annual Healthcare Conference in San Francisco (CA USA), on January 12, 2015. He shared how this strategic integration will enable the company to expand its preeminent immunosequencing research platform and clinical diagnostic products. He also participated on a panel with other leaders from Foundation Medicine, Invitae, and Regeneron who are similarly focused on accelerating the adoption of NGS for diagnostic applications.

Adaptive Biotechnologies Corp. is a platform-based, diagnostic-driven company that utilizes NGS to profile T-cell and B-cell receptors. This advance enables the comprehensive characterization of the adaptive immune system, which is the primary defense against cancer. By incorporating immunosequencing into clinical care, Adaptive can enhance the diagnosis, prognosis, and tracking of cancer patients.

Adaptive helps researchers make discoveries in oncology, autoimmune disorders, and infectious diseases by offering fee-for-service access to its proprietary immune profiling sequencing technology, which is now available to facilitate the integration of immunosequencing into research centers.

Sequenta, Inc. was founded in 2008 and has focused on the development of clinical diagnostics using immunosequencing. Sequenta markets a laboratory developed test for use in the diagnosis and monitoring of minimal residual disease in blood cancers.

Related Links:

Adaptive Biotechnologies 
Sequenta


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.